Taxotere
Taxotere is a clinically established anti-neoplastic chemotherapy medication belonging to the taxane drug class. It works by binding to and stabilizing tubulin in microtubules, preventing cell division and leading to the death of rapidly multiplying cancer cells.
Dosage by Body Weight
Taxotere is administered strictly via intravenous infusion by healthcare professionals in a specialized clinical setting. Standard dosages range from 75 mg/m² to 100 mg/m² administered over 1 hour every 3 weeks. Dosages are calculated individually based on Body Surface Area (BSA) rather than body weight alone. Patients must be premedicated with corticosteroids (such as dexamethasone) starting the day before infusion to reduce fluid retention and hypersensitivity reactions.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight. |
| 5-7 kg | Not recommended | N/A | Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight. |
| 8-10 kg | Not recommended | N/A | Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight. |
| 11-15 kg | Not recommended | N/A | Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight. |
| 16-20 kg | Not recommended | N/A | Pediatric safety and efficacy have not been established. This chemotherapy drug is dosed according to Body Surface Area (BSA) rather than standard body weight. |
Formulation
Purpose
Treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck.
Generic Name
DocetaxelScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.